TGA warns of cardiac and infection risk with ibrutinib

The Product Information (PI) for ibrutinib is being updated to reflect new safety information following reports of ventricular tachyarrhythmia, hepatitis B reactivation and severe opportunistic infections. According to a TGA Medicines Safety Update, the tyrosine kinase inhibitor has been associated with 52 cases of ventricular tachyarrhythmia. “Based on current evidence, the role of ibrutinib in causing ...